Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.

Fengjuan JiangHui LiuFengping PengZhaoyun LiuKai DingJia SongLijuan LiJin ChenQing ShaoSiyang YanKim De VeirmanKarin VanderkerkenWenhui Lei

Published in: Cancer biology & medicine (2021)

C3a activated osteoclasts by regulating the PI3K/PDK1/SGK3 pathways in MM patients, which was reduced using a SGK inhibitor. Overall, our results identified potential therapeutic targets and strategies for MBD patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
multiple myeloma
peritoneal dialysis
risk assessment
climate change
bone loss